Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

NIAID awards more than $12 million for the development of antiviral therapies

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

21 Nov 2022

Scientists identify a class of drugs that may prevent alcohol use disorder in people with PTSD

Survivors of abuse and trauma are vastly more likely than other people to develop alcohol use disorder (AUD); according to some estimates, as many as three-quarters of people with post-traumatic stress disorder (PTSD) report drinking problems.

21 Nov 2022

Researchers to develop brain imaging radiotracers for better understanding of Alzheimer's, autism

Emory researchers are on the cusp of seeing in real time how brain diseases like Alzheimer's and autism spectrum disorder affect a patient's brain function.

21 Nov 2022

Molecular motion of many 'undruggable' proteins reveals previously unseen binding sites

Studying the molecular motion of proteins reveals previously unseen binding sites that could be targeted by new drug candidate molecules.

21 Nov 2022

New Community of Experts launched to harness social media data for patient-centric drug development

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has launched a new Community of Experts (CoE) to harness real-world data from social media.

21 Nov 2022

Augmented drug preferentially eliminates cancer cells but does not harm healthy cells

Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a "prodrug" -; a medicine designed to release its payload in a particular area of the body and in no other areas.

17 Nov 2022

Novel nasal vaccine approach induces potent lung immunity and protection against SARS-CoV-2

Researchers from the Centenary Institute and the University of Sydney have developed a new nasal vaccination strategy that induces potent lung immunity and protection against the SARS-CoV-2 coronavirus.

16 Nov 2022

Sanford Burnham Prebys researchers receive ACS grants to advance work on difficult-to-treat cancers

Two faculty members from Sanford Burnham Prebys have been awarded grants from the American Cancer Society (ACS), the largest not-for-profit funding body for scientists studying cancer. Associate Professor Cosimo Commisso, Ph.D., and Assistant Professor Svasti Haricharan, Ph.D., each received competitive awards to advance their work on difficult-to-treat cancers.

15 Nov 2022

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

During the conference, we caught up with some of the speakers to learn more about their work, what they were presenting, and their thoughts about the future of Oncology and Precision Medicine.

15 Nov 2022

New fentanyl vaccine could prevent deadly opioid from entering the brain

A research team led by the University of Houston has developed a vaccine targeting the dangerous synthetic opioid fentanyl that could block its ability to enter the brain, thus eliminating the drug's "high."

14 Nov 2022

PALS program effective in ensuring diverse representation in lupus clinical trials

The Lupus Research Alliance and its affiliate Lupus Therapeutics presented data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus Studies (PALS), in increasing knowledge, perception, and willingness among people with Systemic Lupus Erythematosus (SLE) to participate in clinical trials.

14 Nov 2022

Harnessing the natural potential of venom for drug discovery

Steven Trim, Founder and Cheif Scientific Officer at Venomtech, tells NewsMedical how UK-based Venomtech® harnesses the power of naturally-produced venoms obtained from a collection of nearly 200 species of spiders, scorpions, and centipedes to create compound libraries for drug discovery.

From INTEGRA Biosciences 14 Nov 2022

Cancer Research Horizons: The Innovation Engine of Cancer Research UK

Following ELRIG 2022, News-Medical speaks with Cancer Research Horizons, the innovation engine of Cancer Research UK about their efforts to advance the drug discovery sector.

From Cancer Research UK 14 Nov 2022

ELRIG: Bringing Life Sciences and Drug Discovery Communities Together

We spoke to ELRIG about the evolving landscape of the drug discovery sector, and what actions they are taking to continue to support individuals in this space.

11 Nov 2022

New approach can help design shorter, more powerful trials to assess Parkinson’s drugs

Testing whether a new drug impacts the progression of Parkinson's disease takes years, in part because the disease often advances so slowly.

10 Nov 2022

EVIDENT and Ultivue collaborate to advance multiplex slide imaging and spatial analysis in translational research

Evident Corporation, a premier manufacturer of life science imaging systems, and Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announced a collaborative agreement to promote whole slide imaging using multiplexed immunofluorescence (mIF) assays to advance translational research in the Americas.

From Evident Corporation - Life Sciences 10 Nov 2022

Collaboration aims to develop new medicines for neurodegenerative diseases

The ALBORADA Drug Discovery Institute (ADDI) today (Tuesday 8 November) announced that it will collaborate with pharmaceutical company YD Global Life Science (YDGLS) to develop inhibitors of the unfolded protein response for the treatment of the diseases that cause dementia.

9 Nov 2022

Drug Discovery News and Research

Further Reading

NIAID awards more than $12 million for the development of antiviral therapies

Scientists identify a class of drugs that may prevent alcohol use disorder in people with PTSD

Researchers to develop brain imaging radiotracers for better understanding of Alzheimer's, autism

Molecular motion of many 'undruggable' proteins reveals previously unseen binding sites

New Community of Experts launched to harness social media data for patient-centric drug development

Augmented drug preferentially eliminates cancer cells but does not harm healthy cells

Novel nasal vaccine approach induces potent lung immunity and protection against SARS-CoV-2

Sanford Burnham Prebys researchers receive ACS grants to advance work on difficult-to-treat cancers

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

New fentanyl vaccine could prevent deadly opioid from entering the brain

PALS program effective in ensuring diverse representation in lupus clinical trials

Harnessing the natural potential of venom for drug discovery

Cancer Research Horizons: The Innovation Engine of Cancer Research UK

ELRIG: Bringing Life Sciences and Drug Discovery Communities Together

New approach can help design shorter, more powerful trials to assess Parkinson’s drugs

EVIDENT and Ultivue collaborate to advance multiplex slide imaging and spatial analysis in translational research

Collaboration aims to develop new medicines for neurodegenerative diseases

Blood pressure drug associated with lower risk of Alzheimer's disease in Black patients

Scientists uncover a key property needed for CELMoD drugs to be effective

Accelerating Scientific Discoveries through Advanced Data Analysis Platforms

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News